Retour à la liste des essais cliniquesLung cancer

BGB-LC-201

A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

Ouvert à Paris depuis le : 13/05/2024
Public cible : Adult
Phase : Phase II

Description de l'essai

To assess the antitumor activity of;tislelizumab plus investigational agent(s);with or without chemotherapy.

Url of the trial

Investigateur principal

NICOLAS GIRARD

Professeur - Médecin

Contacter